# A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

> **NCT00001043** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 20 (actual)

## Conditions studied

- HIV Infections
- HIV Seronegativity

## Interventions

- **BIOLOGICAL:** gp160 Vaccine (Immuno-AG)

## Key facts

- **NCT ID:** NCT00001043
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1997-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001043, "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00001043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*